Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) are surging Friday morning as related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S. patent.

Here’s what investors need to know.

• Jupiter Neurosciences stock is surging to new heights today. What’s behind JUNS gains?

New Patent Expands IP Portfolio

The United States Patent and Trademark Office granted PharmAla U.S. Patent No. 12,679,817, covering cost-effective, scalable manufacturing processes for single-enantiomer MDMA and MBDB compounds. This patent strengthens the intellectual property foundation for PharmAla’s lead drug candidate, ALA-002.

Jupiter Deal Triggers APA-01 Strategy Shift

The updates follow a July 2026 agreement in which PharmAla granted Jupiter Neurosciences exclusive U.S. rights to ALA-002. Citing this transaction as proof of its ability to directly monetize assets on favorable terms, PharmAla exercised its option to cancel a proposed licensing deal for its APA-01 compound with Restora Neurosciences.

PharmAla retains full ownership of APA-01 and plans to evaluate future in-house and co-development pathways directly.

JUNS Shares Surge Friday Morning

JUNS Price Action: Jupiter Neurosciences shares were up 68.86% at $8.73 during premarket trading on Friday, according to Benzinga Pro data.

Image: Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.